"Chile Pharmaceuticals & Healthcare Report Q4 2015" now available at Fast Market Research

From: Fast Market Research, Inc.
Published: Sun Nov 01 2015

Highlighted by the passing of the 'Ricarte Soto Law', Chile will maintain its attractiveness as a growth market for drugmakers as the government displays a firm commitment to expanding public access to health services over the forecast period. In addition, the rising incidence of chron i c, non - communicable disease will coincide with a high reliance on imported pharmaceuticals to safeguard the value share of patented prescription treatments. However, a dependence on the export of copper and the import of natural gas will expose Chile's vulnerable household spending to unexpected demand side shocks from fluctuating commodity prices.

Headline Expenditure Projections

Full Report Details at
- http://www.fastmr.com/prod/1058367_chile_pharmaceuticals.aspx?afid=302

Pharmaceuticals: From CLP1,947.99bn (USD4.0bn) in 2014 to CLP2,093.42bn (USD3.30bn) in 2015; +7.5% in local currency terms and -17.7% in US dollar terms. Forecast revised down wards from Q 2 15.
Healthcare: From CLP11,161bn (USD19.56bn) in 2014 to CLP12,064.37bn (USD19.00bn) in 2015; +8.1% in local currency terms and -2.8% in US dollar terms. Forecast revised down wards from Q 2 15.

Risk/Reward Index

In BMI's Q315 Risk Reward Index, Chile remains ranked sixth out of the 18 markets in the Americas matrix with a slightly reduced score of 52.7 out of 100; down from in Q215. President Bachelet's centre-left government will increasingly focus on improving Chile's regulatory framework, placing an emphasis on raising standards for quality assurance compliance potentially raising operating costs. However, the senate health committee decision to markedly improve public spending on a healthcare with the 'Ricarte Soto' Law highlights growing improvement in Chilean's access to many services. BMI believes that this trend will work to boost access to and consumption of high-cost medicines in the country, making it a more attractive destination for drugmakers in the long-term.

The Chile Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Chile Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Chile pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Chile, to test other views - a key input for successful budgeting and strategic business planning in the Chilean pharmaceutical and healthcare market.
* Target business opportunities and risks in the Chilean pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Chile.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bahrain Pharmaceuticals & Healthcare Report Q4 2015
- Romania Pharmaceuticals & Healthcare Report Q4 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2015
- Peru Pharmaceuticals & Healthcare Report Q4 2015
- Latvia Pharmaceuticals & Healthcare Report Q4 2015

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »